Novel missense variants cause intermediate phenotypes in the phenotypic spectrum of SLC5A6-related disorders.
Yasuhiro UtsunoKeisuke HamadaKohei HamanakaKeita MiyoshiKeiji TsuchimotoSatoshi SunadaToshiyuki ItaiMasamune SakamotoNaomi TsuchidaYuri UchiyamaEriko KoshimizuAtsushi FujitaSatoko MiyatakeKazuharu MisawaTakeshi MizuguchiYasuhito KatoKuniaki SaitoKazuhiro OgataNaomichi MatsumotoPublished in: Journal of human genetics (2023)
SLC5A6 encodes the sodium-dependent multivitamin transporter, a transmembrane protein that uptakes biotin, pantothenic acid, and lipoic acid. Biallelic SLC5A6 variants cause sodium-dependent multivitamin transporter deficiency (SMVTD) and childhood-onset biotin-responsive peripheral motor neuropathy (COMNB), which both respond well to replacement therapy with the above three nutrients. SMVTD usually presents with various symptoms in multiple organs, such as gastrointestinal hemorrhage, brain atrophy, and global developmental delay, at birth or in infancy. Without nutrient replacement therapy, SMVTD can be lethal in early childhood. COMNB is clinically milder and has a later onset than SMVTD, at approximately 10 years of age. COMNB symptoms are mostly limited to peripheral motor neuropathy. Here we report three patients from one Japanese family harboring novel compound heterozygous missense variants in SLC5A6, namely NM_021095.4:c.[221C>T];[642G>C] p.[(Ser74Phe)];[(Gln214His)]. Both variants were predicted to be deleterious through multiple lines of evidence, including amino acid conservation, in silico predictions of pathogenicity, and protein structure considerations. Drosophila analysis also showed c.221C>T to be pathogenic. All three patients had congenital brain cysts on neonatal cranial imaging, but no other morphological abnormalities. They also had a mild motor developmental delay that almost completely resolved despite no treatment. In terms of severity, their phenotypes were intermediate between SMVTD and COMNB. From these findings we propose a new SLC5A6-related disorder, spontaneously remitting developmental delay with brain cysts (SRDDBC) whose phenotypic severity is between that of SMVTD and COMNB. Further clinical and genetic evidence is needed to support our suggestion.
Keyphrases
- replacement therapy
- end stage renal disease
- copy number
- amino acid
- chronic kidney disease
- ejection fraction
- newly diagnosed
- multiple sclerosis
- resting state
- prognostic factors
- peritoneal dialysis
- rheumatoid arthritis
- pregnant women
- body mass index
- young adults
- functional connectivity
- patient reported outcomes
- staphylococcus aureus
- photodynamic therapy
- cancer therapy
- dna methylation
- heavy metals
- small molecule
- physical activity
- cerebral ischemia
- blood brain barrier
- pseudomonas aeruginosa
- autism spectrum disorder
- risk assessment
- patient reported
- weight loss
- binding protein
- gestational age
- chemotherapy induced